Skip to main content
Premium Trial:

Request an Annual Quote

RareCyte Secures $24M to Advance Spatial Biology Platform, Expand Globally

NEW YORK – Life science company RareCyte said on Thursday that it completed $24 million in financing from both new and existing investors.

Arboretum Ventures led the financing, along with several other new investors, including F-Prime Capital, Logos Capital, and Agilent Technologies. Existing investors HealthQuest Capital, 5AM Ventures, and RareCyte founder Ron Seubert also participated.

RareCyte anticipates that the financing will help further develop its proprietary Orion Spatial Biology platform, designed for high-resolution spatial analysis of tissue samples.

The platform shipped to early adopter sites last year and the company stated that it is increasing production at its Seattle headquarters.

"We are thrilled to have Arboretum Ventures lead this new funding round," Joe Victor, RareCyte's president and CEO, said in a statement.

"This funding will allow RareCyte to fast-track important new applications and capabilities for our Orion spatial biology platform," he added, "and accelerate the expansion of global sales and marketing channels for all of our products including our latest tissue and liquid biopsy applications."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.